Hospital Virgen de la Arrixaca -ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study

    Journal of Geriatric Cardiology, Vol. 21, Núm. 7, pp. 723-732

2023

  1. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

2022

  1. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

    Cardiology Journal, Vol. 29, Núm. 6, pp. 936-947

  2. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  3. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46

  4. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

    Journal of comparative effectiveness research, Vol. 11, Núm. 16, pp. 1173-1184

2021

  1. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: Impact of inappropriate doses (the EMIR study)

    Journal of Comparative Effectiveness Research, Vol. 10, Núm. 7, pp. 583-593

2020

  1. Management of patients with heart failure treated in cardiology consultations: IC-BERG Study

    Revista Clinica Espanola, Vol. 220, Núm. 6, pp. 339-349

2019

  1. Recommendations to improve the management and the prognosis of patients with heart failure

    Future Cardiology, Vol. 16, Núm. 1, pp. 1-4